The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease

被引:15
作者
Makitalo, Signar [1 ]
Mellgren, Asa [2 ,3 ]
Borgh, Ellen [4 ]
Kilander, Lena [5 ]
Skillback, Tobias [6 ]
Zetterberg, Henrik [6 ,7 ]
Gisslen, Magnus [3 ]
机构
[1] Gavle Cent Hosp, Dept Infect Dis, S-80187 Gavle, Sweden
[2] South Alvsborg Hosp, Clin Infect Dis, Boras, Sweden
[3] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Infect Dis, Gothenburg, Sweden
[4] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Resp Med, Gothenburg, Sweden
[5] Uppsala Univ, Dept Publ Hlth & Caring Sci Geriatr, Uppsala, Sweden
[6] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden
[7] UCL Inst Neurol, London, England
来源
AIDS RESEARCH AND THERAPY | 2015年 / 12卷
基金
瑞典研究理事会;
关键词
Alzheimer's disease; HIV; CSF biomarkers; NEUROFILAMENT PROTEIN NFL; CENTRAL-NERVOUS-SYSTEM; ANTIRETROVIRAL THERAPY; LIFE EXPECTANCY; TAU-PROTEIN; DEMENTIA; CSF; INDIVIDUALS; DIAGNOSIS; MARKER;
D O I
10.1186/s12981-015-0063-x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
It is a challenge to differentiate between HIV-associated neurocognitive disorders (HAND) and other types of neurocognitive disease in the ageing HIV-infected population. Here we describe a 63 year old HIV-infected woman who had a history, neuropsychological test result, and PET examination consistent with characteristic Alzheimer's disease (AD). The cerebrospinal fluid (CSF) biomarker profile was analogous to the profile typically found in AD in HIV-negative patients with increased t-tau and p-tau, a decreased level of A beta 42 and normal levels of CSF neurofilament light protein and sAPP alpha and sAPP beta, distinctly different from findings in HIV-associated dementia (HAD). Assessment of CSF biomarkers may be a valuable tool for clinicians to distinguish between HAD and AD.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting
    Malnar, Martina
    Kosicek, Marko
    Bene, Raphael
    Tarnik, Iva Petek
    Pavelin, Sanda
    Babic, Ivana
    Brajenovic-Milic, Bojana
    Hecimovic, Hrvoje
    Titlic, Marina
    Trkanjec, Zlatko
    Demarin, Vida
    Hecimovic, Silva
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2012, 72 (03) : 264 - 271
  • [22] β-amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease
    Andreasen, N
    Blennow, K
    PEPTIDES, 2002, 23 (07) : 1205 - 1214
  • [23] Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals
    Letendre, Scott L.
    Zheng, Jialin C.
    Kaul, Marcus
    Yiannoutsos, Constantin T.
    Ellis, Ronald J.
    Taylor, Michael J.
    Marquie-Beck, Jennifer
    Navia, Bradford
    JOURNAL OF NEUROVIROLOGY, 2011, 17 (01) : 63 - 69
  • [24] Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study
    Lleo, Alberto
    Alcolea, Daniel
    Martinez-Lage, Pablo
    Scheltens, Philip
    Parnetti, Lucilla
    Poirier, Judes
    Simonsen, Anja H.
    Verbeek, Marcel M.
    Rosa-Neto, Pedro
    Slot, Rosalinde E. R.
    Tainta, Mikel
    Izaguirre, Andrea
    Reijs, Babette L. R.
    Farotti, Lucia
    Tsolaki, Magda
    Vandenbergue, Rik
    Freund-Levi, Yvonne
    Verhey, Frans R. J.
    Clarimon, Jordi
    Fortea, Juan
    Frolich, Lutz
    Santana, Isabel
    Luis Molinuevo, Jose
    Lehmann, Sylvain
    Visser, Pieter J.
    Teunissen, Charlotte E.
    Zetterberg, Henrik
    Blennow, Kaj
    ALZHEIMERS & DEMENTIA, 2019, 15 (06) : 742 - 753
  • [25] Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects
    Shaw, Leslie M.
    Vanderstichele, Hugo
    Knapik-Czajka, Malgorzata
    Clark, Christopher M.
    Aisen, Paul S.
    Petersen, Ronald C.
    Blennow, Kaj
    Soares, Holly
    Simon, Adam
    Lewczuk, Piotr
    Dean, Robert
    Siemers, Eric
    Potter, William
    Lee, Virginia M. -Y.
    Trojanowski, John Q.
    ANNALS OF NEUROLOGY, 2009, 65 (04) : 403 - 413
  • [26] Aβ42 as a Biomarker of Alzheimer's Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?
    Boschi, Silvia
    Roveta, Fausto
    Grassini, Alberto
    Marcinno, Andrea
    Cermelli, Aurora
    Ferrandes, Fabio
    Rainero, Innocenzo
    Rubino, Elisa
    BRAIN SCIENCES, 2022, 12 (12)
  • [27] Cerebrospinal fluid biomarker for Parkinson's disease: An overview
    Maass, Fabian
    Schulz, Isabel
    Lingor, Paul
    Mollenhauer, Brit
    Baehr, Mathias
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2019, 97 : 60 - 66
  • [28] Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease
    Guo, Liang-Hao
    Alexopoulos, Panagiotis
    Perneczky, Robert
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2013, 263 (07) : 553 - 560
  • [29] Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia
    Kidemet-Piskac, Spomenka
    Leko, Mirjana Babic
    Blazekovic, Antonela
    Horvat, Lea Langer
    Klepac, Natasa
    Sonicki, Zdenko
    Kolenc, Danijela
    Hof, Patrick R.
    Boban, Marina
    Mimica, Ninoslav
    Borovecki, Fran
    Simic, Goran
    CNS NEUROSCIENCE & THERAPEUTICS, 2018, 24 (08) : 734 - 740
  • [30] Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis
    Bjerke, Maria
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 62 (03) : 1199 - 1209